Kazan Federal University, Kremlyovskaya St, 18, Kazan 420000, Russia.
Nizhny Novgorod State Medical Academy, Minin and Pozharsky Square 10/1, Nizhny Novgorod 603005, Russia.
Dis Markers. 2017;2017:8216723. doi: 10.1155/2017/8216723. Epub 2017 Aug 7.
The definition of new markers of local and systemic inflammation of chronic obstructive pulmonary disease (COPD) is one of the priority directions in the study of pathogenesis and diagnostic methods improvement for this disease. We investigated 91 patients with COPD and 21 healthy nonsmokers. The levels of soluble CD25, CD38, CD8, and HLA-I-CD8 molecules in the blood serum and exhaled breath condensate (EBC) in moderate-to-severe COPD patients during exacerbation and stable phase were studied. An unidirectional change in the content of sCD25, sCD38, and sCD8 molecules with increasing severity of COPD was detected. The correlations between the parameters of lung function and sCD8, sCD25, and sHLA-I-CD8 levels in the blood serum and EBC were discovered in patients with severe COPD. The findings suggest a pathogenetic role of the investigated soluble molecules of the COPD development and allow considering the content of sCD8, sCD25, and sHLA-I-CD8 molecules as additional novel systemic and endobronchial markers of the progression of chronic inflammation of this disease.
慢性阻塞性肺疾病(COPD)局部和全身炎症新标志物的定义是该疾病发病机制和诊断方法改进研究的优先方向之一。我们研究了 91 例 COPD 患者和 21 例健康不吸烟者。在 COPD 中度至重度患者加重期和稳定期,研究了血清和呼出气冷凝液(EBC)中可溶性 CD25、CD38、CD8 和 HLA-I-CD8 分子的水平。随着 COPD 严重程度的增加,sCD25、sCD38 和 sCD8 分子的含量呈单向变化。在重度 COPD 患者中,发现了肺功能参数与血清和 EBC 中 sCD8、sCD25 和 sHLA-I-CD8 水平之间的相关性。这些发现表明所研究的可溶性分子在 COPD 发展中的发病机制作用,并允许将 sCD8、sCD25 和 sHLA-I-CD8 分子的含量视为该疾病慢性炎症进展的额外新型系统和支气管内标志物。